Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Cardiff Oncology, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.23 | -$0.16 | -$0.19 |
| Q2 2025 | 2 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2025 | 2 | -$0.20 | -$0.20 | -$0.20 |
| Q4 2025 | 3 | -$0.22 | -$0.22 | -$0.22 |
| Q1 2026 | 2 | -$0.21 | -$0.21 | -$0.21 |
| Q2 2026 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q4 2026 | 2 | -$0.25 | -$0.25 | -$0.25 |
| Q1 2027 | 2 | -$0.29 | -$0.29 | -$0.29 |
| Q2 2027 | 1 | -$0.29 | -$0.29 | -$0.29 |
| Q3 2027 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q4 2027 | 2 | -$0.30 | -$0.30 | -$0.30 |
Cardiff Oncology, Inc. Earnings Date And Information
Cardiff Oncology, Inc. last posted its earnings results on Thursday, February 27th, 2025. The company reported $-0.21 earnings per share for the quarter, topping analysts' consensus estimates of $-0.26 by $0.05. The company had revenue of 151,000 for the quarter and had revenue of 683,000 for the year. Cardiff Oncology, Inc. has generated $-1 earnings per share over the last year ($-0.95 diluted earnings per share) and currently has a price-to-earnings ratio of -3.08. Cardiff Oncology, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 30th, 2025 based on prior year's report dates.
Cardiff Oncology, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/27/2025 | Q4 2024 | -$0.26 | -$0.25 | 0.01 | $100,000 | $151,000 |
| 11/07/2024 | Q3 2024 | -$0.27 | -$0.25 | 0.02 | $70,000 | $165,000 |
| 08/08/2024 | Q2 2024 | -$0.25 | -$0.26 | -0.01 | $58,750 | $163,000 |
| 05/02/2024 | Q1 2024 | -$0.25 | -$0.22 | 0.03 | $62,500 | $205,000 |
| 02/29/2024 | Q4 2023 | -$0.26 | -$0.21 | 0.05 | $50,000 | $156,000 |
| 11/02/2023 | Q3 2023 | -$0.29 | -$0.22 | 0.07 | $50,000 | $141,000 |
| 08/09/2023 | Q2 2023 | -$0.27 | -$0.25 | 0.02 | $50,000 | $108,000 |
| 05/04/2023 | Q1 2023 | -$0.23 | -$0.23 | 0 | $65,600 | $83,000 |
| 03/02/2023 | Q4 2022 | -$0.25 | -$0.18 | 0.07 | $73,250 | $128,000 |
| 11/03/2022 | Q3 2022 | -$0.27 | -$0.19 | 0.08 | $68,200 | $93,000 |
| 08/04/2022 | Q2 2022 | -$0.25 | -$0.24 | 0.01 | $93,000 | $91,000 |
| 05/05/2022 | Q1 2022 | -$0.23 | -$0.25 | -0.02 | $56,600 | $74,000 |
| 02/24/2022 | Q4 2021 | -$0.17 | -$0.23 | -0.06 | $41,000 | $133,000 |
| 11/04/2021 | Q3 2021 | -$0.17 | -$0.17 | 0 | $40,000 | $86,000 |
| 08/05/2021 | Q2 2021 | -$0.15 | -$0.17 | -0.02 | $152,500 | $68,000 |
| 05/06/2021 | Q1 2021 | -$0.14 | -$0.14 | 0 | $152,500 | $72,000 |
| 02/25/2021 | Q4 2020 | -$0.15 | -$0.28 | -0.13 | $43,333 | $119,255 |
| 11/05/2020 | Q3 2020 | -$0.20 | -$0.19 | 0.01 | $50,000 | $136,401 |
| 08/11/2020 | Q2 2020 | -$0.24 | -$0.28 | -0.04 | $29,676 | $42,633 |
| 05/07/2020 | Q1 2020 | N/A | -$0.41 | N/A | N/A | $67,704 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Cardiff Oncology, Inc. Earnings: FAQ's
Cardiff Oncology, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 30th, 2025 based offlast year's report dates.
In the previous quarter, Cardiff Oncology, Inc. (:CRDF) reported $-0.21 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.26 by $0.05.
The conference call for Cardiff Oncology, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Cardiff Oncology, Inc.'s latest earnings report can be read online.
Cardiff Oncology, Inc. (:CRDF) has a recorded annual revenue of $683,000.
Cardiff Oncology, Inc. (:CRDF) has a recorded net income of $-45,431,000.Cardiff Oncology, Inc. has generated $-0.95 earnings per share over the last four quarters.
Cardiff Oncology, Inc. (:CRDF) has a price-to-earnings ratio of -3.08 and price/earnings-to-growth ratio is 0.72.